追蹤
Ignace Vergote
Ignace Vergote
Professor of Gynecologic Oncology, University of Leuven
在 uzleuven.be 的電子郵件地址已通過驗證
標題
引用次數
引用次數
年份
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
I Vergote, CG Tropé, F Amant, GB Kristensen, T Ehlen, N Johnson, ...
New England Journal of Medicine 363 (10), 943-953, 2010
2736*2010
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ...
New England Journal of Medicine 375 (22), 2154-2164, 2016
23752016
Endometrial cancer
F Amant, P Moerman, P Neven, D Timmerman, E Van Limbergen, ...
The Lancet 366 (9484), 491-505, 2005
23552005
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
New England Journal of Medicine 366 (15), 1382-1392, 2012
20732012
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised …
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
The lancet oncology 15 (8), 852-861, 2014
16952014
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial
E Pujade-Lauraine, F Hilpert, B Weber, A Reuss, A Poveda, G Kristensen, ...
Obstetrical & Gynecological Survey 69 (7), 402-404, 2014
16642014
Niraparib in patients with newly diagnosed advanced ovarian cancer
A González-Martín, B Pothuri, I Vergote, R DePont Christensen, ...
New England Journal of Medicine 381 (25), 2391-2402, 2019
16632019
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised …
E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ...
The lancet oncology 18 (9), 1274-1284, 2017
16382017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
15682017
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
I Ray-Coquard, P Pautier, S Pignata, D Pérol, A González-Martín, ...
New England Journal of Medicine 381 (25), 2416-2428, 2019
14882019
Epithelial ovarian cancer
S Lheureux, C Gourley, I Vergote, AM Oza
The Lancet 393 (10177), 1240-1253, 2019
13092019
Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
MJ Piccart, K Bertelsen, K James, J Cassidy, C Mangioni, E Simonsen, ...
Journal of the National Cancer Institute 92 (9), 699-708, 2000
13052000
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
N Concin, X Matias-Guiu, I Vergote, D Cibula, MR Mirza, S Marnitz, ...
International Journal of Gynecologic Cancer 31 (1), 2021
12962021
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and …
J Bonneterre, B Thürlimann, JFR Robertson, M Krzakowski, L Mauriac, ...
Journal of Clinical Oncology 18 (22), 3748-3757, 2000
11242000
Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group
D Timmerman, L Valentin, TH Bourne, WP Collins, H Verrelst, I Vergote
Ultrasound in Obstetrics and Gynecology: The Official Journal of the …, 2000
10692000
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N Colombo, C Sessa, A Du Bois, J Ledermann, WG McCluggage, ...
Annals of Oncology 30 (5), 672-705, 2019
10272019
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer.
AG Van der Zee, MH Oonk, JA De Hullu, AC Ansink, I Vergote, ...
9082008
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
A Howell, JFR Robertson, J Quaresma Albano, A Aschermannova, ...
Journal of Clinical Oncology 20 (16), 3396-3403, 2002
8682002
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the …
J Pfisterer, M Plante, I Vergote, A du Bois, H Hirte, AJ Lacave, U Wagner, ...
Journal of Clinical Oncology 24 (29), 4699-4707, 2006
8512006
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
I Vergote, J De Brabanter, A Fyles, K Bertelsen, N Einhorn, P Sevelda, ...
The lancet 357 (9251), 176-182, 2001
7912001
系統目前無法執行作業,請稍後再試。
文章 1–20